TransMedics Group (TMDX) Tops Q2 EPS by 14c ; Offers Guidance

TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of $0.35, $0.14 better than the analyst estimate of $0.21. Revenue for the quarter came in at $114.3 million versus the consensus estimate of $98.96 million.

GUIDANCE:

TransMedics Group sees FY2024 revenue of $425-445 million, versus the consensus of $401.5 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
• USA Rare Earth secures $1.55 billion SPV for Serra Verde offtake